BMS’ Sotyktu (Deucravacitinib) Wins EC Approval to Treat Adults with Active Psoriatic Arthritis (PsA)

Why It Matters

Sotyktu provides an oral, non‑biologic option for patients who have failed conventional DMARDs, potentially reshaping treatment algorithms and expanding market share in a space dominated by injectable biologics.

Key Takeaways

• EC greenlights Sotyktu for active PsA in adults
• Trials showed ACR20 and MDA improvements versus placebo
• Physical QoL scores improved and held through week 52
• Offers oral alternative to injectable biologics for DMARD‑failed patients

Pulse Analysis

Psoriatic arthritis affects roughly 30 million people worldwide, and many still rely on injectable biologics after conventional disease‑modifying antirheumatic drugs (DMARDs) fall short. The chronic nature of the disease, coupled with the inconvenience of frequent injections, has driven a demand for effective oral therapies that can be integrated into patients’ daily routines without compromising efficacy. In Europe, clinicians have long awaited a drug that can target the underlying inflammatory pathways while offering the convenience of a pill, positioning Sotyktu as a timely entrant.

Sotyktu’s mechanism hinges on selective inhibition of tyrosine kinase 2 (TYK2), a key node in the interleukin‑23/IL‑12 signaling cascade that drives psoriatic inflammation. In the POETYK PsA‑1 trial, 670 biologic‑naïve participants receiving Sotyktu achieved a 55 % ACR20 response versus 30 % on placebo, while the POETYK PsA‑2 cohort—comprising patients previously exposed to TNF‑α inhibitors—recorded a 48 % response versus 22 % placebo. Both studies also met the minimal disease activity endpoint and demonstrated sustained improvements in the SF‑36 physical component, underscoring the drug’s capacity to enhance functional outcomes over a full year.

From a commercial perspective, Sotyktu’s approval diversifies BMS’s rheumatology portfolio and challenges incumbent biologics such as adalimumab and secukinumab. An oral formulation can attract patients hesitant about injections, potentially increasing adherence and market penetration. Moreover, the drug’s safety profile—highlighted by a comparable adverse‑event rate to placebo—may ease payer concerns and facilitate broader reimbursement. As the EU market embraces this new class, competitors are likely to accelerate development of their own oral TYK2 inhibitors, intensifying innovation in the PsA space.